A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II α

被引:11
|
作者
Jensen, LH
Renodon-Cornière, A
Nitiss, KC
Hill, BT
Nitiss, JL
Jensen, PB
Sehested, M
机构
[1] Rigshosp, Lab Ctr, Dept Pathol, DK-2100 Copenhagen, Denmark
[2] Rigshosp, Finsen Ctr, Lab Expt Med Oncol, DK-2100 Copenhagen, Denmark
[3] St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38018 USA
[4] Ctr Rech Pierre Fabre, Div Cancerol, F-81100 Castres, France
关键词
topoisomerase II; epipodophyllotoxin; chemotherapy; DNA damage; surface plasmon resonance; mutation;
D O I
10.1016/S0006-2952(03)00342-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
F 11782 is a novel epipodophyllotoxin that targets eukaryotic topoisomerases and inhibits enzyme binding to DNA. While F 11782 has not been found to stabilize either topoisomerase I or topoisomerase II covalent complexes, drug treatment appears to result in DNA damage. F 11782 has also been shown to inhibit the DNA nucleotide excision repair (NER) pathway. Bisdioxopiperazine-resistant small cell lung cancer (SCLC) OC-NYH/Y165S and Chinese hamster ovary (CHO) CHO/159-1 cells having functional Y49F and Y165S mutations in the topoisomerase II alpha isoform were both resistant to F 11782. The catalytic activity of purified human Y50F and Y165S mutant topoisomerase 11 a (Y50F in the human protein corresponds to Y49F in the CHO protein) was likewise resistant to the inhibitory action of F 11782. F11782 was also found to induce a non-covalent salt-stable complex of human topoisomerase II with DNA that was ATP-independent. F 11782 thus displays a dual mechanism of action on human topoisomerase II alpha, reducing its affinity for DNA while also stabilizing the protein bound in the form of a salt-stable complex. Our results suggest that topoisomerase II alpha is a target of F 11782 in vivo, and that F 11782 may act as a novel topoisomerase II poison. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:623 / 631
页数:9
相关论文
共 50 条
  • [31] Phenotypic Discovery of Thiocarbohydrazone with Anticancer Properties and Catalytic Inhibition of Human DNA Topoisomerase IIα
    Cvijetic, Ilija N.
    Herlah, Barbara
    Marinkovic, Aleksandar
    Perdih, Andrej
    Bjelogrlic, Snezana K.
    PHARMACEUTICALS, 2023, 16 (03)
  • [32] Dioxime palladium (II) complex: Synthesis, characterization, and dual anticancer mechanisms of topoisomerase II inhibition and Bax/caspase 3
    Al-Harbi, Sami A.
    APPLIED ORGANOMETALLIC CHEMISTRY, 2024, 38 (09)
  • [33] Promising Dual Anticancer and Antimetastatic Action by a Cu(II) Complex Derived from Acylhydrazone on Human Osteosarcoma Models
    Santa Maria de la Parra, Lucia
    Romo, Adolfo I. B.
    Rodriguez-Lopez, Joaquin
    Nascimento, Otaciro R.
    Echeverria, Gustavo A.
    Piro, Oscar E.
    Leon, Ignacio E.
    INORGANIC CHEMISTRY, 2024, 63 (11) : 4925 - 4938
  • [34] Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIα and β -: Distinct mode of action of two derivatives
    Krishna, ADS
    Panda, G
    Kondapi, AK
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2005, 438 (02) : 206 - 216
  • [35] The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning
    Bruno, Peter M.
    Lu, Mengrou
    Dennis, Kady A.
    Inam, Haider
    Moore, Connor J.
    Sheehe, John
    Elledge, Stephen J.
    Hemann, Michael T.
    Pritchard, Justin R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2020, 117 (08) : 4053 - 4060
  • [36] DNA topoisomerase II as the target for the anticancer drug TOP-53: Mechanistic basis for drug action
    Byl, JAW
    Cline, SD
    Utsugi, T
    Kobunai, T
    Yamada, Y
    Osheroff, N
    BIOCHEMISTRY, 2001, 40 (03) : 712 - 718
  • [37] Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells
    Minderman, H
    Wrzosek, C
    Cao, SS
    Utsugi, T
    Kobunai, T
    Yamada, Y
    Rustum, YM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (01) : 78 - 84
  • [38] Mechanism of action of the dual topoisomerase-I and -II inhibitor TAS-103 and activity against (multi)drug resistant cells
    Hans Minderman
    Carol Wrzosek
    Shousong Cao
    Teruhiro Utsugi
    Takashi Kobunai
    Yuji Yamada
    Youcef M. Rustum
    Cancer Chemotherapy and Pharmacology, 2000, 45 : 78 - 84
  • [39] Dual action photosensitive platinum(II) anticancer prodrugs with photoreleasable azide ligands
    Shi, Huayun
    Clarkson, Guy J.
    Sadler, Peter J.
    INORGANICA CHIMICA ACTA, 2019, 489 : 230 - 235
  • [40] Dual Inhibitors of Human DNA Topoisomerase II and Other Cancer Related Targets
    Skok, Ziga
    Zidar, Nace
    Kikelj, Danijel
    Ilas, Janez
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (03) : 884 - 904